# Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing

Study · id `cardio:ct-nct04798768` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04798768](<https://clinicaltrials.gov/study/NCT04798768>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT04798768

Browse, organ or system: Heart  
Browse, condition area: Heart rhythm problems  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 297 participants.

## Technical summary

Registry record NCT04798768. Allocation not applicable; no masking; primary purpose treatment. Start 2021-07-20 (actual); primary completion 2024-05-06 (actual). Results posted on 2025-06-26.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 297 participants (enrolled count; ClinicalTrials.gov record NCT04798768, source copy `cardio:ctgov-nct04798768-2026-11-12`, retrieved 2026-11-18)
- Started: 2021-07-20 (actual) (ClinicalTrials.gov record NCT04798768, source copy `cardio:ctgov-nct04798768-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2024-05-06 (actual) (ClinicalTrials.gov record NCT04798768, source copy `cardio:ctgov-nct04798768-2026-11-12`, retrieved 2026-11-18)
- Completion: 2030-12-31 (anticipated) (ClinicalTrials.gov record NCT04798768, source copy `cardio:ctgov-nct04798768-2026-11-12`, retrieved 2026-11-18)
- Results first posted: 2025-06-26 (ClinicalTrials.gov record NCT04798768, source copy `cardio:ctgov-nct04798768-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Austria; Canada; Czechia; France; Italy; Netherlands; Spain; United Kingdom (ClinicalTrials.gov record NCT04798768, source copy `cardio:ctgov-nct04798768-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04798768-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: Effectiveness of the EMPOWER™ Modular Pacing System and EMBLEM™ Subcutaneous ICD to Communicate Antitachycardia Pacing
- Acronym: MODULAR ATP
- Condition: Tachycardia, Ventricular
- Condition: Arrhythmia, Ventricular
- Intervention (Device): mCRM Therapy System
- Lead sponsor: Boston Scientific Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Ventricular tachycardia (`cardio:ventricular-tachycardia`)
- Registry lists this organization as the lead sponsor: Boston Scientific (`cardio:boston-scientific`)

## Provenance

Content hash: 2a73ceb6ec070fc5dcc0ff9dab81758740d7c84eed058cc2138bfb5ca60c61d8
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
